Supplemental study support that saves Q4 timelines

If your dashboards show lagging recruitment or slowing referrals, now’s the time to pivot. A focused rescue strategy can close gaps and restore momentum before the new year.
Study Finds High Menstrual Pain, but Low Diagnosis Rates for Dysmenorrhea

SubjectWell’s real-world study found that an overwhelming majority of women surveyed experienced significant menstrual pain consistent with dysmenorrhea, but only a very small percentage had received a formal diagnosis or sought care.
SubjectWell Unveils New Science-Driven Framework to Transform Protocol Design, Recruitment, Engagement, and Retention

By integrating Patient Burden Index (PBI), Site Burden Index (SBI), and standards-of-care data into its modeling and execution, SubjectWell is redefining how sponsors design protocols, forecast feasibility, drive enrollment, and sustain long-term patient participation.
SubjectWell unveils new science-driven framework to transform protocol design, recruitment, engagement, and retention

SubjectWell’s new evidence-based framework integrates burden indices and standards-of-care data to help sponsors design smarter trials, predict performance, and enhance patient and site experience.
Social Media’s Expanding Role in Women’s Health and Clinical Trial Recruitment

SubjectWell SVP of Marketing, Suzanne Harris, discusses our latest peer-reviewed research that uses social media as a health resource and recruitment engine.
SubjectWell wins 2025 GDUSA Health + Wellness Design Award for Brand Reinvention

Award recognizes design excellence in advancing health, wellness and patient engagement.
Keeping clinical trial patients engaged during the holidays

How to stay connected and consistent—even when your patients are in holiday mode.
Predictability starts with better site support

How integrated services create consistency, confidence, and acceleration across global trials.
From weight loss to liver health: Why GLP-1 innovation is turning toward MASH

As the GLP-1 market expands into MASH, sponsors will face the same engagement challenges we saw in obesity—only with higher complexity. Success will depend on how well we understand patient motivators and make trials accessible.